Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance

The Pharmacogenomics Journal volume 10, pages 513–523 (2010)Cite this article

Subjects

Abstract

The dose of docetaxel is currently calculated based on body surface area and does not reflect the pharmacokinetic, metabolic potential or genetic background of the patients. The influence of genetic variation on the clearance of docetaxel was analysed in a two-stage analysis. In step one, 583 single-nucleotide polymorphisms (SNPs) in 203 genes were genotyped on samples from 24 patients with locally advanced non-small cell lung cancer. We found that many of the genes harbour several SNPs associated with clearance of docetaxel. Most notably these were four SNPs in EGF, three SNPs in PRDX4 and XPC, and two SNPs in GSTA4, TGFBR2, TNFAIP2, BCL2, DPYD and EGFR. The multiple SNPs per gene suggested the existence of common haplotypes associated with clearance. These were confirmed with detailed haplotype analysis. On the basis of analysis of variance (ANOVA), quantitative mutual information score (QMIS) and Kruskal–Wallis (KW) analysis SNPs significantly associated with clearance of docetaxel were confirmed for GSTA4, PRDX4, TGFBR2 and XPC and additional putative markers were found in CYP2C8, EPHX1, IGF2, IL1R2, MAPK7, NDUFB4, TGFBR3, TPMT (2 SNPs), (P<0.05 or borderline significant for all three methods, 14 SNPs in total). In step two, these 14 SNPs were genotyped in additional 9 samples and the results combined with the genotyping results from the first step. For 7 of the 14 SNPs, the results are still significant/borderline significant by all three methods: ANOVA, QMIS and KW analysis strengthening our hypothesis that they are associated with the clearance of docetaxel.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

AAG:

α1-acid glycoprotein

AUC:

area under the curve

BSA:

body surface area

HPLC:

high performance liquid chromatography

KW:

Kruskal–Wallis

LD:

linkage disequilibrium

LOOCV:

leave one out cross validation

MAF:

minor allele frequency

MIS:

mutual information score

NSCLC:

non-small cell lung cancer

OMIM:

online Mendelian inheritance in man

QMIS:

quantitative mutual information score

ROS:

reactive oxygen species

SNPs:

single-nucleotide polymorphisms

UHT:

ultra high throughput

References

  1. Morse DL, Gray H, Payne CM, Gillies RJ . Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4: 1495–1504.

    Article  CAS  PubMed  Google Scholar 

  2. Wang LG, Liu XM, Kreis W, Budman DR . The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44: 355–361.

    Article  CAS  PubMed  Google Scholar 

  3. Baker SD, Sparreboom A, Verweij J . Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006; 45: 235–252.

    Article  CAS  PubMed  Google Scholar 

  4. Caffo O . Radiosensitization with chemotherapeutic agents. Lung Cancer 2001; 34 (Suppl 4): S81–S90.

    Article  PubMed  Google Scholar 

  5. Brunsvig PF, Hatlevoll R, Berg R, Lauvvang G, Owre K, Wang M et al. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years′ follow-up. Lung Cancer 2005; 50: 97–105.

    Article  PubMed  Google Scholar 

  6. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009; 85: 155–163.

    Article  CAS  PubMed  Google Scholar 

  7. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB . A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153–172.

    Article  CAS  PubMed  Google Scholar 

  8. Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH et al. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem 2000; 275: 39907–39913.

    Article  CAS  PubMed  Google Scholar 

  9. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313–322.

    Article  CAS  PubMed  Google Scholar 

  10. Venugopal R, Jaiswal AK . Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996; 93: 14960–14965.

    Article  CAS  PubMed  Google Scholar 

  11. Dai Y, Rashba-Step J, Cederbaum AI . Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 1993; 32: 6928–6937.

    Article  CAS  PubMed  Google Scholar 

  12. Morel Y, Barouki R . Repression of gene expression by oxidative stress. Biochem J 1999; 342 (Pt 3): 481–496.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Raza H, John A . 4-hydroxynonenal induces mitochondrial oxidative stress, apoptosis and expression of glutathione S-transferase A4-4 and cytochrome P450 2E1 in PC12 cells. Toxicol Appl Pharmacol 2006; 216: 309–318.

    Article  CAS  PubMed  Google Scholar 

  14. Park JY, Shigenaga MK, Ames BN . Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci USA 1996; 93: 2322–2327.

    Article  CAS  PubMed  Google Scholar 

  15. Edvardsen H, Irene Grenaker AG, Tsalenko A, Mulcahy T, Yuryev A, Lindersson M et al. Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds. Pharmacogenet Genomics 2006; 16: 207–217.

    CAS  PubMed  Google Scholar 

  16. Gurney H . Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590–2611.

    Article  CAS  PubMed  Google Scholar 

  17. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H . High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. BMC Clin Pharmacol 2006; 6: 2.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tsalenko A, Ben-Dor A, Cox N, Yakhini Z . Methods for analysis and visualization of SNP genotype data for complex diseases. Pac Symp Biocomput 2003: 548–561.

  19. Rice JA . Mathematical Statistics and Data Analysis, 3rd edn. Australia; Belmont, CA: Thompson/Brooks/Cole, c2007.

    Google Scholar 

  20. Tsalenko A, Sharan R, Edvardsen H, Kristensen VN, Borresen-Dale AL, Ben-Dor A et al. Analysis of SNP-expression association matrices. J BioComput Bioinformat 2006; 4: 259–274.

    Article  CAS  Google Scholar 

  21. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003; 100: 2532–2537.

    Article  CAS  PubMed  Google Scholar 

  22. Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.

    Article  CAS  Google Scholar 

  23. McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD et al. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 2005; 41: 1086–1094.

    Article  CAS  PubMed  Google Scholar 

  24. Kristensen VN, Edvardsen H, Tsalenko A, Nordgard SH, Sorlie T, Sharan R et al. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc Natl Acad Sci USA 2006; 103: 7735–7740.

    Article  CAS  PubMed  Google Scholar 

  25. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422–431.

    Article  CAS  PubMed  Google Scholar 

  26. Lee AJ, Conney AH, Zhu BT . Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol. Cancer Res 2003; 63: 6532–6536.

    CAS  PubMed  Google Scholar 

  27. Chen H, Fantel AG, Juchau MR . Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metab Dispos 2000; 28: 1051–1057.

    CAS  PubMed  Google Scholar 

  28. Hubatsch I, Ridderstrom M, Mannervik B . Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem J 1998; 330: 175–179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wang WL, Yeh SF, Chang YI, Hsiao SF, Lian WN, Lin CH et al. PICK1, an anchoring protein that specifically targets protein kinase Calpha to mitochondria selectively upon serum stimulation in NIH 3T3 cells. J Biol Chem 2003; 278: 37705–37712.

    Article  CAS  PubMed  Google Scholar 

  30. Nagase H, Mao JH, Balmain A . Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 2003; 63: 4849–4853.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This project was supported by the Norwegian Cancer Association (project number D-03067 and D-99061) and the National Programme for Research in Functional Genomics in Norway (FUGE, project numbers 151924/150 and 15204/150), funded by the Research Council of Norway. Genotyping was partly performed at the Uppsala SNP technology platform, which is funded by the Swedish Wallenberg Consortium North (WCN).

Author information

Authors and Affiliations

  1. Department of Genetics, Institute of Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway

    H Edvardsen, H Solvang, A-L Børresen-Dale & V N Kristensen

  2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    H Edvardsen, A-L Børresen-Dale & V N Kristensen

  3. Cancer Clinic, Oslo University Hospital Radiumhospitalet, Oslo, Norway

    P F Brunsvig & S Aamdal

  4. Institute of Basic Medical Research, Faculty of Medicine, University of Oslo, Oslo, Norway

    H Solvang

  5. Agilent Technologies, Santa Clara, CA, USA

    A Tsalenko & Z Yakhini

  6. Department of Pharmacology, Oslo University Hospital Radiumhospitalet, Oslo, Norway

    A Andersen & H Olsen

  7. Department of Medical Sciences, Uppsala University, Uppsala, Sweden

    A-C Syvanen

Authors
  1. H Edvardsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P F Brunsvig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Solvang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Tsalenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A-C Syvanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z Yakhini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A-L Børresen-Dale
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Aamdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. V N Kristensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V N Kristensen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edvardsen, H., Brunsvig, P., Solvang, H. et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J 10, 513–523 (2010). https://doi.org/10.1038/tpj.2010.6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.6

Keywords

This article is cited by

Search

Advanced search

Quick links